Print Page | Contact Us | Sign In | Join ACAM
ACAM Integrative Medicine Blog
Blog Home All Blogs

FDA: Additions/modifications to the list of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness

Posted By Administration, Thursday, October 6, 2016
Updated: Friday, October 7, 2016

Today, the U.S. Food and Drug Administration issued a final rule amending FDA’s list of drug products that may not be compounded under certain sections of the Food, Drug, and Cosmetic Act (FD&C Act) that allow the marketing of unapproved compounded drugs.

Drug products on the list may not be compounded because the drug products have been withdrawn or removed from the market for safety or effectiveness reasons. The list appears in the Code of Federal Regulations at Title 21, section 216.24.

The final rule:

  • Adds 24 types of drugs to the withdrawn or removed list.
  • Modifies the withdrawn or removed list to allow one type of drug product to be compounded under certain circumstances.
  • Clarifies that the withdrawn or removed list applies to sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

In addition, FDA published a discussion in the Federal Register that clarifies the procedure FDA intends to use to amend the withdrawn or removed list.

FDA’s website has additional information on compounding.

Tags:  chelation  chelation therapy  Code of Federal Regulations at Title 21  compounding  fda  fda compounding  section 216.24 

Share |
PermalinkComments (0)
 
Connect With Us

380 Ice Center Lane, Suite C

Bozeman, MT 59718

1.800.532.3688

Our mission

The American College for Advancement in Medicine (ACAM) is a not-for-profit organization dedicated to educating physicians and other health care professionals on the safe and effective application of integrative medicine.